By Fineline Cube 
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA) has accepted for review a new indication filing for Sishujing (anrikefon/HSK21542), its proprietary selective peripheral kappa receptor agonist, for the treatment of postoperative pain. The novel analgesic leverages a unique mechanism that avoids central nervous system penetration, potentially eliminating opioid-related side effects while maintaining effective pain control.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) |
| Product | Sishujing (anrikefon/HSK21542) – selective peripheral kappa receptor agonist |
| New Indication | Postoperative pain |
| Regulatory Status | NMPA filing accepted for review |
| Existing Approvals | Mild-to-moderate abdominal surgery pain; moderate-to-severe pruritus in hemodialysis patients |
| Mechanism Advantage | Does not cross blood-brain barrier, avoiding central opioid side effects |
Product Profile & Innovation
- Molecule Type: Selective peripheral kappa receptor agonist with high selectivity and affinity
- Mechanism of Action:
- Synergistically regulates potassium and calcium currents via G protein participation
- Blocks itching signal transduction and inhibits dorsal root ganglion excitability
- Reduces release of inflammatory factors and neurotransmitters
- Key Differentiator: Peripheral restriction eliminates hallucinations, addiction, and respiratory depression risks
- Therapeutic Expansion: Builds on established post-surgical pain approval to broader postoperative pain market
- Patient Population: Millions of surgical procedures annually in China requiring effective, non-opioid analgesia
Strategic Significance
| Aspect | Details |
|---|---|
| Opioid Crisis Alternative | Addresses urgent need for non-addictive pain management in surgical settings |
| Franchise Expansion | Leverages existing regulatory and commercial infrastructure for rapid market penetration |
| Safety Profile | Unique peripheral mechanism provides significant safety advantage over traditional opioids |
| Market Opportunity | Postoperative pain represents multi-billion dollar global market with strong growth trajectory |
The new indication filing demonstrates Haisco’s strategy of maximizing the value of its innovative peripheral kappa agonist platform across multiple pain and pruritus indications.
Market Impact & Outlook
- China Surgical Market: Over 50 million surgical procedures annually creating substantial demand for effective analgesics
- Competitive Landscape | Limited non-opioid alternatives with comparable efficacy; first-mover advantage in peripheral kappa space
- Reimbursement Potential | Strong likelihood of National Reimbursement Drug List inclusion given unmet need and safety profile
- Revenue Implications | Combined indications could generate ¥800 million–1.2 billion ($55–82 million) annually
- Global Strategy | Success in China may catalyze international development partnerships for global markets
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory filings, clinical development, market opportunities, and commercial expectations for Sishujing. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption rates, and pricing negotiations.-Fineline Info & Tech